Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DQ7-CHAR NK cells
- Development stage
- Preclinical
- Lead developer
- Erasmus MC
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
DQ7-CHAR NK cells are chimeric HLA antibody receptor (CHAR) natural killer (NK) cells engineered to target and eliminate HLA-DQ7-specific B cells. Developed by researchers at Hospital Clinic de Barcelona, Leiden University Medical Center, Erasmus MC, and IDIBAPS, these cells are designed to address antibody-mediated rejection (ABMR) and facilitate desensitization in sensitized solid organ (e.g., renal) transplant patients. The CHAR construct is composed of HLA-DQA1*05:01 and HLA-DQB1*03:01 (DQ7) chains combined with a CLIP peptide and intracellular costimulatory and signaling domains. Transduced into NK92 or primary NK cells, DQ7-CHAR NK cells selectively target and eliminate B cells expressing HLA-DQ7-specific B-cell receptors (BCRs) without affecting other antibody-producing B cells.
- Other names
- HLA-DQ7 chimeric HLA antibody receptor NK cellsHLA-DQ-7 chimeric HLA antibody receptor NK cellsHLA-DQ 7 chimeric HLA antibody receptor NK cellsHLA-DQ7-CHAR NK cellsHLA-DQ-7-CHAR NK cellsHLA-DQ 7-CHAR NK cells
Beyond the preview
Go deeper on DQ7-CHAR NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DQ7-CHAR NK cells.